Array Biopharma Inc (NASDAQ:ARRY) Director Kyle Lefkoff sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, February 6th. The shares were sold at an average price of $20.60, for a total value of $721,000.00. Following the sale, the director now owns 47,720 shares in the company, valued at $983,032. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

ARRY stock opened at $21.81 on Monday. The company has a current ratio of 6.31, a quick ratio of 5.62 and a debt-to-equity ratio of 0.46. Array Biopharma Inc has a 52-week low of $12.56 and a 52-week high of $22.80. The company has a market cap of $4.76 billion, a price-to-earnings ratio of -29.88 and a beta of 1.37.

Array Biopharma (NASDAQ:ARRY) last posted its quarterly earnings data on Tuesday, February 5th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.11. Array Biopharma had a negative return on equity of 44.37% and a negative net margin of 46.20%. The company had revenue of $82.55 million for the quarter, compared to the consensus estimate of $52.44 million. During the same period in the previous year, the business earned ($0.17) EPS. Array Biopharma’s revenue for the quarter was up 95.5% compared to the same quarter last year. On average, equities analysts forecast that Array Biopharma Inc will post -0.6 EPS for the current fiscal year.

Several brokerages recently commented on ARRY. BidaskClub upgraded Array Biopharma from a “buy” rating to a “strong-buy” rating in a report on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Array Biopharma in a report on Wednesday, February 6th. Zacks Investment Research upgraded Array Biopharma from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Tuesday, February 5th. Finally, Piper Jaffray Companies restated a “positive” rating and set a $28.00 price objective on shares of Array Biopharma in a report on Tuesday, January 15th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $25.89.

Hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. increased its holdings in Array Biopharma by 635.8% during the 4th quarter. Meeder Asset Management Inc. now owns 2,097 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,812 shares during the last quarter. Exane Derivatives purchased a new stake in Array Biopharma during the 4th quarter worth approximately $39,000. IFP Advisors Inc acquired a new position in shares of Array Biopharma in the 4th quarter worth approximately $40,000. Bank of Montreal Can grew its position in shares of Array Biopharma by 47.3% in the 4th quarter. Bank of Montreal Can now owns 5,879 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,888 shares in the last quarter. Finally, Glenmede Trust Co. NA grew its position in shares of Array Biopharma by 54.2% in the 3rd quarter. Glenmede Trust Co. NA now owns 10,385 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 3,650 shares in the last quarter. Institutional investors own 94.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Array Biopharma Inc (ARRY) Director Sells $721,000.00 in Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2019/02/11/array-biopharma-inc-arry-director-sells-721000-00-in-stock.html.

Array Biopharma Company Profile

Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation.

Featured Article: Google Finance Portfolio Workaround

Insider Buying and Selling by Quarter for Array Biopharma (NASDAQ:ARRY)

Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.